×
About 26,855 results

The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants
https://clinicaltrials.gov/ct2/show/NCT03779776

Sep 10th, 2021 - Bronchopulmonary dysplasia (BPD) is the most prevalent longterm morbidity among surviving extremely preterm infants and has a multifactorial etiology. BPD is associated with later risk of reactive airways disease, such as asthma, post neonatal mortality and adverse neurodevelopmental outcomes.Retinopathy of prematurity (ROP) is a common retinal neovascular disorder and a major cause of vision i...

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04635683

Sep 10th, 2021 - PRIMARY OBJECTIVE: I. Determine the recommended phase 2 dose (RP2D) and toxicity of lenalidomide, umbralisib and ublituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL). SECONDARY OBJECTIVES: I. Determine the overall response rate (ORR) for patients with relapsed or refractory follicular lymphoma (FL) treated at the RP2D. II. Determ...

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04722146

Sep 10th, 2021 - The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04108195

Sep 10th, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or teclistamab may lead to enhanced clinical responses in treatment of relapsed or refractory multiple myeloma through multiple mechanisms of action. Dara...

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Respons...
https://clinicaltrials.gov/ct2/show/NCT05013008

Sep 10th, 2021 - Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly. When CKD happens in people with type 2 diabetes mellitus, a condition characterized by high blood sugar levels, CKD is also referred to as diabetic kidney disease (DKD). FIGARO-BM is an add-on study in which blood draws that ...

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junc...
https://clinicaltrials.gov/ct2/show/NCT03504397

Sep 10th, 2021 - The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up.

Energy Therapy and Meditation Based Practice for Sleep Difficulties
https://clinicaltrials.gov/ct2/show/NCT05003050

Sep 10th, 2021 - BACKGROUND AND RATIONALE The liver is a vital organ responsible for enabling our body to digest food and rid itself of toxic substances. There are more than 100 types of liver disease affecting both children and adults presenting with a wide variety of symptoms. Young people (YP) with chronic illness tend to have a higher rate of mental health problems compared to the general population, with p...

Effects of Homocysteine in Myocardial Infarction Patients in a Tertiary Care Hospital of Pakistan
https://clinicaltrials.gov/ct2/show/NCT05011032

Sep 10th, 2021 - Excess of low density lipoproteins, high blood pressure, obesity, excess of blood sugar levels, smoking and sedentary life style are the known modifiable risk factors causing cardiovascular disease specifically Coronary disease. There can be some other substances which can additionally affect the human cardiac physiology as well i.e. high levels of Homocysteine molecule in the blood. The advers...

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02532257

Sep 10th, 2021 - PRIMARY OBJECTIVES: I. To evaluate the efficacy of ibrutinib combined with rituximab and lenalidomide in patients with previously untreated follicular lymphoma (FL) and marginal zone lymphoma (determined by progression-free survival at 2 years). SECONDARY OBJECTIVES: I. To evaluate the efficacy of ibrutinib combined with rituximab and lenalidomide in subjects with FL as assessed by complete res...

Sirtuin-NAD+ Activator in Alzheimer's Disease
https://clinicaltrials.gov/ct2/show/NCT05040321

Sep 10th, 2021 - The sirtuin family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase enzymes are important regulators of the aging process (1-5) and mediate many of the beneficial effects of caloric restriction (6-9). The upregulation of the sirtuin-NAD+ pathway by increasing intracellular NAD+ through administration of NAD precursors, such as β nicotinamide mononucleotide (βNMN), has been show...

Effectiveness of Olive Oil Local Application in Orthodontic Patients.
https://clinicaltrials.gov/ct2/show/NCT05040620

Sep 10th, 2021 - During the orthodontic treatment, the friction between the bracket and the arch-wire could prevent the action of forces required for a particular tooth movement. Studies demonstrated that approximately 12 to 60% of the force used to move a tooth is dissipated in the form of friction. Consequently, a delay could occur in the biological response to orthodontic movement. The most important factors...

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?
https://clinicaltrials.gov/ct2/show/NCT05033483

Sep 10th, 2021 - BACKGROUND: Many women take iron-containing supplements during pregnancy. Indeed, the World Health Organization recommends that all pregnant women in low-income countries take an iron supplement containing 60 mg/day of elemental iron to reduce iron deficiency and iron-deficiency anaemia. However, oral iron has poor bioavailability, less than 10% absorbed with the remainder passing into the larg...

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT01130519

Sep 9th, 2021 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a familial cancer syndrome characterized by a propensity for developing renal cancer, uterine and cutaneous leiomyomas.The kidney cancer associated with HLRCC is associated with HLRCC is clinically aggressive and is characterized by unique histopathologic features that are sometimes described as type2 papillary RCC. Germline...

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
https://clinicaltrials.gov/ct2/show/NCT02728102

Sep 9th, 2021 - The study is a three-arm, phase II randomized, open-labeled clinical trial that randomizes patients to vaccination with Dendritic Cell (DC)/myeloma fusions/GM-CSF plus lenalidomide maintenance therapy or lenalidomide maintenance therapy with or without GM-CSF following autologous transplant as part of upfront treatment for patients diagnosed with multiple myeloma. Patients are randomized approx...

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
https://clinicaltrials.gov/ct2/show/NCT02005289

Sep 9th, 2021 - PRIMARY OBJECTIVES: I. To determine the overall response rate (ORR) at 6 months for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)/prolymphocytic leukemia (PLL) treated with the combination of MOR00208 plus lenalidomide. II. To determine the overall response rate (ORR) at 6 months for patients with treatment-naive CLL/SLL/PLL treated wit...

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
https://clinicaltrials.gov/ct2/show/NCT02997228

Sep 9th, 2021 - PRIMARY OBJECTIVE: I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab. SECONDARY OBJECTIVES: I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in S...

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
https://clinicaltrials.gov/ct2/show/NCT04757610

Sep 9th, 2021 - A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Establishment and Evaluation of Multimodal Image Recognition System of Glioma Based on Deep Learning
https://clinicaltrials.gov/ct2/show/NCT04407039

Sep 9th, 2021 - Multimodal Image Recognition System of Glioma Molecular imaging is the use of imaging methods to display specific molecules at the tissue level, cellular level, and subcellular level, reflecting changes in the molecular level in the living state, and performing qualitative and quantitative researches on the biological behavior of the imaging aspect. Multimodal Image Recognition System includes ...

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)
https://clinicaltrials.gov/ct2/show/NCT03133546

Sep 9th, 2021 - Lung cancer has been the most common carcinoma in the world for several decades. Non-small cell lung carcinoma (NSCLC) represents approximately 80-85% of all lung cancers. At the time of diagnosis approximately 70% of NSCLC patients already have advanced or metastatic disease not amenable to surgical resection. A significant percentage of early stage NSCLC patients who have undergone surgery su...

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT04876248

Sep 9th, 2021 - PRIMARY OBJECTIVE: I. Assess the minimal residual disease (MRD) negative rate at the end (after 12 months) of consolidation with belantamab mafodotin in combination with lenalidomide post autologous stem cell transplantation. SECONDARY OBJECTIVE: I. Assess sustained MRD negative rate, progression free survival (PFS) and overall survival (OS). OUTLINE: Patients receive belantamab mafodotin intra...